Literature DB >> 21956654

Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.

Maurizio Rossini1, Silvano Adami, Ombretta Viapiana, Riccardo Ortolani, Antonio Vella, Elena Fracassi, Davide Gatti.   

Abstract

The use of intravenous nitrogen-containing bisphosphonates (N-BPs) is associated with the appearance of an acute phase response (APR) in a proportion of the patients for reasons that are poorly understood. The APR was attributed to the indirect activation of γδ T cells with the release of interferon-γ and tumor necrosis factor (TNF). Forty patients with postmenopausal or senile osteoporosis (age range = 53-91 years) never previously treated with intravenous (i.v.) bisphosphonate, received a single 5-mg zoledronic acid (ZOL) iv infusion over 15 minutes. White blood cells were counted and analyzed with an automated hematology analyzer (ADVIA 2120i Siemens, New York, USA) and by flow cytometer (BD FACSCanto, Becton Dickinson). The occurrence of APR was defined by the occurrence of fever (>37 °C) during the next 2 days. Forty-two percent of patients (17 of 40) receiving the infusion of ZOL experienced an APR. Compared with the others they were younger (69 ± 7 years versus 74 ± 8 years; p = 0.06), and both the proportion and absolute number of γδ T cells were significant higher (p = 0.02 and p = 0.013, respectively). Nonsignificant differences were found between the two groups for white blood cells and for the other circulating lymphocyte subpopulations. Age was inversely correlated with circulating γδ T cells (p = 0.003) but the difference between the two groups in circulating γδ T cells persisted for age-adjusted values and vice versa. In conclusion, the results of this study indicate that the number of circulating γδ T cells, together with age, are important determinant of the occurrence of APR after intravenous infusion of ZOL and possibly of any other N-BPs.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21956654     DOI: 10.1002/jbmr.521

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  9 in total

Review 1.  Osteogenesis imperfecta: diagnosis and treatment.

Authors:  A Biggin; C F Munns
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

2.  Surgical trauma and low-dose methylprednisolone modulate the severity of the acute-phase response induced by zoledronic acid infusion.

Authors:  Jian Chen; Lipeng Yu; Lixin Chen; Xuan Wu; Pengyu Tang; Jian Yin; Tao Jiang; Guoyong Yin; Jin Fan
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

3.  The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes.

Authors:  Luca Degli Esposti; Valentina Perrone; Diego Sangiorgi; Margherita Andretta; Fausto Bartolini; Arturo Cavaliere; Andrea Ciaccia; Stefania Dell'orco; Stefano Grego; Sara Salzano; Loredana Ubertazzo; Adriano Vercellone; Davide Gatti; Angelo Fassio; Ombretta Viapiana; Maurizio Rossini; Giovanni Adami
Journal:  J Bone Miner Res       Date:  2021-08-22       Impact factor: 6.390

4.  Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone.

Authors:  Shinichiro Kuroshima; Kirk William Elliott; Junro Yamashita
Journal:  Calcif Tissue Int       Date:  2013-03-17       Impact factor: 4.333

5.  Markers of inflammation after zoledronic acid redosing.

Authors:  Antonis Sykiotis; Garyphallia Papaioannou; Jordan Mavropoulos; Maria Triantaphyllopoulou; Fotini Papandroulaki; Vassiliki Ktena; Stavroula Thanou; Argyris Pardalakis; Aikaterini Kaltsa; Helen Karga
Journal:  J Bone Miner Metab       Date:  2013-05-21       Impact factor: 2.626

Review 6.  γδ T Cell Immunotherapy-A Review.

Authors:  Hirohito Kobayashi; Yoshimasa Tanaka
Journal:  Pharmaceuticals (Basel)       Date:  2015-02-12

7.  Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation.

Authors:  Han-Ching Tseng; Keiichi Kanayama; Kawaljit Kaur; So-Hyun Park; Sil Park; Anna Kozlowska; Shuting Sun; Charles E McKenna; Ichiro Nishimura; Anahid Jewett
Journal:  Oncotarget       Date:  2015-08-21

8.  Efficacy of zoledronic acid for chronic low back pain associated with Modic changes in magnetic resonance imaging.

Authors:  Katri Koivisto; Eero Kyllönen; Marianne Haapea; Jaakko Niinimäki; Kaj Sundqvist; Timo Pehkonen; Seppo Seitsalo; Osmo Tervonen; Jaro Karppinen
Journal:  BMC Musculoskelet Disord       Date:  2014-03-04       Impact factor: 2.362

9.  Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.

Authors:  Masataka Shiraki; Tatsuhiko Kuroda; Yasuhiro Takeuchi; Toshitsugu Sugimoto; Satoshi Tanaka; Hiroaki Suzuki; Kazuki Hiraishi; Toshitaka Nakamura
Journal:  Calcif Tissue Int       Date:  2021-07-10       Impact factor: 4.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.